MicroRNA-224 orchestrates BMP and TGFβ signaling and is a therapeutic target in preclinical pulmonary arterial hypertension
Science Translational Medicine · 02.09.2026 · 18 (865)
DOI: 10.1126/scitranslmed.aef6676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 02.09.2026. Verfasst von Olympia Bikou und 18 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: MicroRNAs, Signal Transduction, Transforming Growth Factor beta, Bone Morphogenetic Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease that leads to right heart failure and ultimately death. Therapeutic options targeting the underlying mechanisms of the disease are urgently needed. MicroRNAs (miRs) have emerged as critical regulators of cardiovascular homeostasis and disease. Here, we identified microRNA-224-5p (miR-224) as a regulator of pulmonary vascular remodeling and delineate its mechanism of action in PAH. miR-224 expression was increased in the lungs of patients with PAH and across multiple experimental models of pulmonary hypertension, including mouse, rat, and pig models, as well as in pulmonary arterial smooth muscle cells (PASMCs) isolated from patients with PAH. In vitro, miR-224 overexpression was sufficient to induce PASMC proliferation. In vivo, adeno-associated virus 1 (AAV1)–mediated overexpression of miR-224 exacerbated PAH in mice, whereas intratracheal delivery of aerosolized AAV1–ToughDecoy–miR-224 or a chemically modified antisense oligonucleotide targeting miR-224 (LNA-224) attenuated disease severity in Sugen/Hypoxia (Su/Hx) and monocrotaline models in both mice and rats. Moreover, SMC-specific inhibition of miR-224 via an AAV1 vector expressing ToughDecoy–miR-224 reversed pulmonary vascular remodeling and improved right ventricular function in the Su/Hx mouse model. Mechanistically, miR-224 targeted multiple components of the bone morphogenetic protein (BMP)/transforming growth factor–β (TGFβ) signaling pathway, leading to suppressed BMP/SMAD signaling and enhanced TGFβ-associated responses. Inhibition of miR-224 restored the balance between growth-inhibitory BMP signaling and growth-promoting TGFβ signaling in PASMCs. Collectively, these findings identify miR-224 as a regulator of pulmonary vascular remodeling and highlight miR-224 inhibition as a promising therapeutic strategy for PAH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Medicine I, LMU University Hospital, Munich, Germany.
- Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, VA, USA.
- Department of Pharmacological Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Cell Biology and Anatomy and Physiology, New York Medical College, Valhalla, NY, USA.
- Institute of Pharmacology and Toxicology, Technical University of Munich (TUM), Munich, Germany.
ORCID-Profile: Olympia Bikou, Aymen Halouani, Yifei Sun, Malik Bisserier, Clemens Eisenacher, Samar A Antar, Petros Avramopoulos, Carlos G Santos-Gallego, Kiyotake Ishikawa, Marc Humbert, Antonio Lax, Stefan Engelhardt, Martin J Walsh, Lahouaria Hadri, Yassine Sassi
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- National Institutes of Health
- American Heart Association
- Deutsche Herzstiftung
- American Lung Association
Zitieren
APA
Bikou, O., Halouani, A., Sun, Y., Bisserier, M., Eisenacher, C., Antar, S. A., Avramopoulos, P., Santos-Gallego, C. G., Swarts, C., Kohlbrenner, E., Ishikawa, K., Humbert, M., Hajjar, R. J., Lax, A., Engelhardt, S., Walsh, M. J., Bonnet, S., Hadri, L., & Sassi, Y. (2026). MicroRNA-224 orchestrates BMP and TGFβ signaling and is a therapeutic target in preclinical pulmonary arterial hypertension. Science Translational Medicine, 18(865). https://doi.org/10.1126/scitranslmed.aef6676
Vancouver
Bikou O, Halouani A, Sun Y, Bisserier M, Eisenacher C, Antar SA, et al. MicroRNA-224 orchestrates BMP and TGFβ signaling and is a therapeutic target in preclinical pulmonary arterial hypertension. Science Translational Medicine. 2026;18(865). doi:10.1126/scitranslmed.aef6676
BibTeX
@article{Bikou2026,
author = {Bikou, Olympia and Halouani, Aymen and Sun, Yifei and Bisserier, Malik and Eisenacher, Clemens and Antar, Samar A and Avramopoulos, Petros and Santos-Gallego, Carlos G and Swarts, Catherine and Kohlbrenner, Erik and Ishikawa, Kiyotake and Humbert, Marc and Hajjar, Roger J and Lax, Antonio and Engelhardt, Stefan and Walsh, Martin J and Bonnet, Sebastien and Hadri, Lahouaria and Sassi, Yassine},
title = {MicroRNA-224 orchestrates BMP and TGFβ signaling and is a therapeutic target in preclinical pulmonary arterial hypertension},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {865},
doi = {10.1126/scitranslmed.aef6676}
}
EUVIMED